GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse Ellipta (umeclidinium), a maintenance treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease (COPD), also known as “chronic bronchitis,” “smoker’s cough” or “emphysema”. 

Incruse Ellipta is a bronchodilator (medicine that helps make breathing easier) and consists of a long-acting muscarinic antagonist (LAMA) known as umeclidinium. 

GSK Associate Medical Director, Dr Navin Singh says the approval is another crucial step forward in the development of GSK’s respiratory portfolio in Australia. 

“We are delighted by the TGA approval of Incruse Ellipta, our first LAMA, which will provide healthcare professionals with a further treatment option for appropriate COPD patients. GSK continues to be committed to developing a range of new therapeutic options that will enable physicians to make treatment choices based on individual patient needs,” said Dr Singh.

For more details, go to: http://www.gsk.com.au/media-centre_detail.aspx?view=755